LLY

1,065.58

-1.06%↓

JNJ

222.68

+0.13%↑

ABBV

212.27

+0.31%↑

UNH

375.95

-0.6%↓

MRK

115.57

+0.93%↑

LLY

1,065.58

-1.06%↓

JNJ

222.68

+0.13%↑

ABBV

212.27

+0.31%↑

UNH

375.95

-0.6%↓

MRK

115.57

+0.93%↑

LLY

1,065.58

-1.06%↓

JNJ

222.68

+0.13%↑

ABBV

212.27

+0.31%↑

UNH

375.95

-0.6%↓

MRK

115.57

+0.93%↑

LLY

1,065.58

-1.06%↓

JNJ

222.68

+0.13%↑

ABBV

212.27

+0.31%↑

UNH

375.95

-0.6%↓

MRK

115.57

+0.93%↑

LLY

1,065.58

-1.06%↓

JNJ

222.68

+0.13%↑

ABBV

212.27

+0.31%↑

UNH

375.95

-0.6%↓

MRK

115.57

+0.93%↑

Inicio・Lista de Acciones・Incyte Corp

Incyte Corp

Abierto

SectorSanidad

93.68 -1.58

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

92.58

Máximo

95.71

Métricas clave
By Trading Economics
Ingresos	4.1M 303M
Ventas	-234M 1.3B
P/B Media del Sector	13.723 50.102
BPA	1.81
Margen de beneficios	23.834
Empleados	2,844
EBITDA	-47M 368M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+11.94% upside

Dividendos
By Dow Jones
Próximas Ganancias	28 jul 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	362M 19B
Apertura anterior	95.26
Cierre anterior	93.68

Noticias sobre sentimiento de mercado

By Acuity

16%

84%

20 / 344 Clasificación en Healthcare

Incyte Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

1 jun 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1 jun 2026, 23:38 UTC

Adquisiciones, fusiones, absorciones

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1 jun 2026, 23:37 UTC

Charlas de Mercado

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1 jun 2026, 23:01 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

1 jun 2026, 23:01 UTC

Charlas de Mercado

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1 jun 2026, 22:08 UTC

Adquisiciones, fusiones, absorciones

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 jun 2026, 22:01 UTC

Adquisiciones, fusiones, absorciones

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1 jun 2026, 22:01 UTC

Adquisiciones, fusiones, absorciones

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1 jun 2026, 21:55 UTC

Adquisiciones, fusiones, absorciones

Greg Abel's Week Is Off to Quite a Start -- WSJ

1 jun 2026, 21:53 UTC

Charlas de Mercado

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1 jun 2026, 21:22 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1 jun 2026, 20:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

1 jun 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

1 jun 2026, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

1 jun 2026, 20:46 UTC

Adquisiciones, fusiones, absorciones

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1 jun 2026, 20:22 UTC

Adquisiciones, fusiones, absorciones

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1 jun 2026, 20:21 UTC

Adquisiciones, fusiones, absorciones

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1 jun 2026, 20:21 UTC

Adquisiciones, fusiones, absorciones

Array Digital Infrastructure Declares $11 Special Div

1 jun 2026, 20:20 UTC

Adquisiciones, fusiones, absorciones

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1 jun 2026, 19:40 UTC

Charlas de Mercado

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1 jun 2026, 19:28 UTC

Charlas de Mercado

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1 jun 2026, 19:01 UTC

Charlas de Mercado

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1 jun 2026, 18:58 UTC

Charlas de Mercado

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1 jun 2026, 18:54 UTC

Adquisiciones, fusiones, absorciones

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1 jun 2026, 18:33 UTC

Charlas de Mercado

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1 jun 2026, 18:32 UTC

Charlas de Mercado

Precious Metals Fall to Start June -- Market Talk

1 jun 2026, 18:00 UTC

Adquisiciones, fusiones, absorciones

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1 jun 2026, 17:18 UTC

Charlas de Mercado

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1 jun 2026, 17:18 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

1 jun 2026, 17:10 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Comparación entre iguales

Cambio de precio

Incyte Corp previsión

Precio Objetivo

By TipRanks

11.94% repunte

Estimación a 12 Meses

Media 108.29 USD 11.94%

Máximo 135 USD

Mínimo 75 USD

De acuerdo con 19 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Incyte Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

19 ratings

Comprar

Mantener

Vender

De acuerdo con 19 analistas que ofrecen calificaciones bursátiles a para Incyte Corp Dist en los últimos 3 meses.

Sentimiento

By Acuity

20 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation